In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on ProQR (PRQR), with a price target of $20.00. The company’s shares closed last Wednesday at $6.01.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 16.9% and a 51.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Deciphera Pharmaceuticals.
Currently, the analyst consensus on ProQR is a Strong Buy with an average price target of $20.00.
See today’s analyst top recommended stocks >>
Based on ProQR’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $13.22 million. In comparison, last year the company had a GAAP net loss of $18.54 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ProQR Therapeutics NV operates as a biopharmaceutical company, which engages in the discovery and development of Ribonucleic Acid RNA based therapeutics for the treatment of genetic disorders. Its initial focus is on the development of a disease-modifying therapy for the treatment of cystic fibrosis. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.
